share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  04/26 17:00
Moomoo AI 已提取核心信息
On April 25, 2024, Clene Inc., along with its wholly owned subsidiary Clene Nanomedicine, Inc., amended and restated key agreements with 4Life Research, LLC, a health supplements supplier and related party. The agreements, originally established in August 2018, include an exclusive supply agreement and a license agreement, collectively known as the Amended 4Life Agreements. Under the supply agreement, 4Life will exclusively purchase certain dietary and non-pharmaceutical products from Clene, with a purchase price set at the company's cost plus 20%. 4Life is obligated to meet minimum sales commitments through 2033, with the potential for exclusivity to become non-exclusive if certain conditions are not met. The license agreement grants 4Life an exclusive license to use, sell, and commercialize the products, with a royalty rate of 3% on incremental sales. Both agreements are set to continue until December 31, 2033, with provisions for early termination under specific circumstances and potential renewal for additional five-year terms. The full text of both agreements has been filed with the SEC and incorporated into Clene's Current Report on Form 8-K.
On April 25, 2024, Clene Inc., along with its wholly owned subsidiary Clene Nanomedicine, Inc., amended and restated key agreements with 4Life Research, LLC, a health supplements supplier and related party. The agreements, originally established in August 2018, include an exclusive supply agreement and a license agreement, collectively known as the Amended 4Life Agreements. Under the supply agreement, 4Life will exclusively purchase certain dietary and non-pharmaceutical products from Clene, with a purchase price set at the company's cost plus 20%. 4Life is obligated to meet minimum sales commitments through 2033, with the potential for exclusivity to become non-exclusive if certain conditions are not met. The license agreement grants 4Life an exclusive license to use, sell, and commercialize the products, with a royalty rate of 3% on incremental sales. Both agreements are set to continue until December 31, 2033, with provisions for early termination under specific circumstances and potential renewal for additional five-year terms. The full text of both agreements has been filed with the SEC and incorporated into Clene's Current Report on Form 8-K.
2024年4月25日，Clene Inc.及其全资子公司Clene Nanomedicine, Inc. 修订并重申了与保健品供应商及关联方4Life Research, LLC的关键协议。这些协议最初于2018年8月订立，包括独家供应协议和许可协议，统称为经修订的4Life协议。根据供应协议，4Life将独家购买Clene的某些膳食和非药品产品，购买价格按公司成本加20％确定。4Life有义务在2033年之前履行最低销售承诺，如果不满足某些条件，排他性可能会变为非排他性。该许可协议授予4Life使用、销售和商业化产品的独家许可，增量销售的特许权使用费为3％。这两项协议都将持续到2033年12月31日，其中规定在特定情况下提前终止，并可能延长五年期限。两份协议的全文已提交给美国证券交易委员会，并已纳入Clene的8-K表最新报告。
2024年4月25日，Clene Inc.及其全资子公司Clene Nanomedicine, Inc. 修订并重申了与保健品供应商及关联方4Life Research, LLC的关键协议。这些协议最初于2018年8月订立，包括独家供应协议和许可协议，统称为经修订的4Life协议。根据供应协议，4Life将独家购买Clene的某些膳食和非药品产品，购买价格按公司成本加20％确定。4Life有义务在2033年之前履行最低销售承诺，如果不满足某些条件，排他性可能会变为非排他性。该许可协议授予4Life使用、销售和商业化产品的独家许可，增量销售的特许权使用费为3％。这两项协议都将持续到2033年12月31日，其中规定在特定情况下提前终止，并可能延长五年期限。两份协议的全文已提交给美国证券交易委员会，并已纳入Clene的8-K表最新报告。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息